Keros Therapeutics Appoints Anne Prener to its Board of Directors

LEXINGTON, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced the appointment of Anne Prener, M.D., Ph.D., to its Board of Directors, effective July 1, 2026.

GlobeNewsWire • Jun 25, 2026

Keros Therapeutics, Inc. (KROS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Keros Therapeutics, Inc. (KROS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • Jun 8, 2026

Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference

LEXINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros' President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 4:00 p.m. Eastern time.

GlobeNewsWire • Jun 1, 2026

KROS Stock Guide to Rinvatercept in DMD and ALS for 2026

Keros heads into 2026 with rinvatercept catalysts in DMD and ALS as investors watch phase II plans, orphan status and early clinical signals.

Zacks Investment Research • May 22, 2026

KROS Turns to Next Wave of TGF-Beta Muscle Therapies

Keros is shifting toward rinvatercept-led neuromuscular development, with phase II plans, early human signals and cash runway shaping the KROS story.

Zacks Investment Research • May 22, 2026

Should You Buy KROS After Q1 Miss and Takeda Deal Reset?

Keros faces a volatile setup after its Q1 miss, with a longer cash runway and leaner costs balanced against uncertain milestone-driven revenue.

Zacks Investment Research • May 22, 2026

Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year

KROS posts a wider Q1 loss as revenues fall due to the absence of license revenues. The company advances rinvatercept and elritercept studies.

Zacks Investment Research • May 15, 2026

Keros Therapeutics Reports Recent First Quarter 2026 Financial Results

LEXINGTON, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today reported financial results for the quarter ended March 31, 2026.

GlobeNewsWire • May 14, 2026

Keros Therapeutics, Inc. (KROS) Reports Q1 Loss, Misses Revenue Estimates

Keros Therapeutics, Inc. (KROS) came out with a quarterly loss of $1.21 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to earnings of $3.62 per share a year ago.

Zacks Investment Research • May 14, 2026

KROS Rinvatercept: What to Know Before DMD Phase II Starts

KROS sharpens focus on rinvatercept as a phase II DMD study looms in 2026, shifting the story toward execution and high-stakes clinical catalysts.

Zacks Investment Research • Apr 20, 2026